Drug intelligence / Profile preview

ACmab1

Development stage: Unknown
Lead developer: Axon Neuroscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**ACmab1** is an investigational monoclonal antibody developed by AXON Neuroscience for the treatment of COVID-19. It is designed to bind the SARS-CoV-2 spike glycoprotein and inhibit viral entry into host cells, functioning as a spike protein inhibitor intended to neutralize the virus. Based on the provided context, ACmab1 is a biologic therapeutic in early clinical development, with activity directed against the coronavirus spike protein as its primary antiviral mechanism.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on ACmab1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACmab1.

Explore the full profile